Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Adeno Associated Virus Equipment Supplied In Europe
4 equipment items found
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
AAV, or adeno-associated virus, is considered the gold standard for in vivo gene delivery transfer and has become the leading viral vector choice for gene therapies today. As one of the field’s most effective delivery tools, AAV has shown strong clinical success and recent improvements in related technology and system approaches have made ...
Manufactured by:SpliceBio based inBarcelona, SPAIN
SpliceBio specializes in addressing the challenges of gene therapy by leveraging engineered split inteins. Traditional adeno-associated virus (AAV) vectors are limited by size, restricting their ability to package only small genes, thus leaving many monogenic diseases without effective treatment solutions. The company has focused on the ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
AAV, or adeno-associated virus, is considered the gold standard for in vivo gene delivery transfer and has become the leading viral vector choice for gene therapies today. As one of the field’s most effective delivery tools, AAV has shown strong clinical success and recent improvements in related technology and system approaches have made ...
Manufactured by:ViruSure GmbH based inVienna, AUSTRIA
Gene therapy has brought hope to many diseases with unmet clinical need. The potential to permanently cure the patient through replacement of a defective gene with a healthy gene underscores the surge of interest in this exciting biopharma ...